Dicerna Pharmaceuticals
2 known investors
The site presents corporate and investor news relating to Novo Nordisk, a pharmaceutical company, including financial reports and clinical trial results for products such as GLP-1 medicines and the hemophilia A treatment denecimig (Mim8).
BiotechHealthtech
Investors Β· 2
Non-dilutive funding Β· 4 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $184.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Dicerna Pharmaceuticals do?
- The site presents corporate and investor news relating to Novo Nordisk, a pharmaceutical company, including financial reports and clinical trial results for products such as GLP-1 medicines and the hemophilia A treatment denecimig (Mim8).
- Who are Dicerna Pharmaceuticals's investors?
- Dicerna Pharmaceuticals's investors include Access Biotechnology, Bain Capital Life Sciences.